Misplaced Pages

Irbesartan

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Avalide) Chemical compound

Pharmaceutical compound
Irbesartan
Clinical data
Pronunciation/ɜːrbəˈsɑːrtən/
Trade namesAprovel, Avapro, others
AHFS/Drugs.comMonograph
MedlinePlusa698009
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classCardiovascular agent
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNINGRx-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability60% to 80%
Protein binding~90%
MetabolismLiver (CYP2C9)
Elimination half-life11 h to 15 h
ExcretionKidney 20%, feces 65%
Identifiers
IUPAC name
  • 2-butyl-3-({4-phenyl}methyl)-1,3-diazaspironon-1-en-4-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.119.966 Edit this at Wikidata
Chemical and physical data
FormulaC25H28N6O
Molar mass428.540 g·mol
3D model (JSmol)
SMILES
  • O=C1N(\C(=N/C12CCCC2)CCCC)Cc5ccc(c3ccccc3c4nnn4)cc5
InChI
  • InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
  • Key:YOSHYTLCDANDAN-UHFFFAOYSA-N
  (verify)

Irbesartan, sold under the brand name Aprovel among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Versions are available as the combination irbesartan/hydrochlorothiazide.

Common side effects include dizziness, diarrhea, feeling tired, muscle pain, and heartburn. Serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the baby and use when breastfeeding is not recommended. It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.

Irbesartan was patented in 1990, and approved for medical use in 1997. It is available as a generic medication. In 2022, it was the 200th most commonly prescribed medication in the United States, with more than 2 million prescriptions.

Medical uses

Irbesartan is used for the treatment of hypertension. It may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 h) or proteinuria (>900 mg/24 h).

Combination with diuretic

Irbesartan is also available in a fixed-dose combination formulation with hydrochlorothiazide, a thiazide diuretic, to achieve an additive antihypertensive effect.

Society and culture

Brand names

It was developed by Sanofi Research (part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the brand names Aprovel, Karvea, and Avapro.

Recalls

See also: Valsartan § recalls, and Angiotensin II receptor blocker § recalls

In 2018, the US Food and Drug Administration (FDA) reported that some versions of the angiotensin II receptor blocker medicines (including valsartan, losartan, irbesartan and other "-sartan" drugs) contain nitrosamine impurities. Health Canada also reported nitrosamine impurities.

The FDA issued revised guidelines about nitrosamine impurities in September 2024.

References

  1. ^ "Irbesartan (Avapro) Use During Pregnancy". Drugs.com. 16 August 2018. Archived from the original on 2 May 2019. Retrieved 19 March 2020.
  2. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
  4. "Aprovel EPAR". European Medicines Agency. 27 August 1997. Archived from the original on 13 June 2024. Retrieved 13 June 2024.
  5. ^ "Irbesartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 30 November 2019. Retrieved 3 March 2019.
  6. ^ "Avalide- irbesartan and hydrochlorothiazide tablet, film coated". DailyMed. 31 July 2018. Archived from the original on 15 February 2018. Retrieved 19 March 2020.
  7. ^ "CoAprovel EPAR". European Medicines Agency. 15 October 1998. Archived from the original on 13 June 2024. Retrieved 13 June 2024.
  8. "Karvezide EPAR". European Medicines Agency (EMA). 16 October 1998. Retrieved 30 August 2024.
  9. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 175. ISBN 9780857113382.
  10. "Irbesartan Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 2 May 2019. Retrieved 3 March 2019.
  11. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 470. ISBN 9783527607495.
  12. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  13. "Irbesartan Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. (September 2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes". The New England Journal of Medicine. 345 (12): 851–860. doi:10.1056/NEJMoa011303. hdl:2445/122787. PMID 11565517.
  15. Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.
  16. "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
  17. "Irbesartan and Hydrochlorothiazide (Professional Patient Advice)". Drugs.com. 5 June 2019. Archived from the original on 20 March 2020. Retrieved 19 March 2020.
  18. "Irbesartan and hydrochlorothiazide Advanced Patient Information". Drugs.com. 24 December 2019. Archived from the original on 20 March 2020. Retrieved 19 March 2020.
  19. "Recalls of Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan". U.S. Food and Drug Administration (FDA). 10 May 2021. Archived from the original on 13 October 2023. Retrieved 30 January 2023.
  20. "Nitrosamine impurities in medications: Guidance". Health Canada. 4 April 2022. Archived from the original on 1 June 2024. Retrieved 24 April 2023.
  21. "Control of Nitrosamine Impurities in Human Drugs". U.S. Food and Drug Administration. 24 February 2021. Retrieved 6 September 2024.
Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors
("-pril")
AIIRAs
("-sartan")
Renin inhibitors
("-kiren")
Dual ACE/NEP inhibitors
Neprilysin inhibitors
Other
Angiotensin receptor modulators
ATRTooltip Angiotensin receptor
Combinations:
Portal: Categories: